Mid-period crossings: the quarter's story is things that started during it and are still completing
The model's full reasoning — Q3 2021 call → NOThe question asks whether management's account of the reported period is built around real business activity that crossed from not-happening to happening partway through the period, and whether management makes clear that this newly started activity is still completing its climb, so the period's reported numbers averaged the 'before' and 'after' and therefore sit below the level at which the business is already running. Let me analyze the transcript carefully. The company is Akebia Therapeutics, developing vadadustat for anemia due to CKD. The PDUFA date is March 29, 2022 (about five months away from the call date of November 9, 2021). The product is NOT yet approved. Key points from the call: - Vadadustat is not yet approved - it's under FDA review - The PDUFA target action date is in March (about 5 months away) - They are preparing for launch but the launch hasn't happened yet - Auryxia is their current commercial product, which has been on the market The question asks about "real business activity that crossed from not-happening to happening partway through the period." Let me look for any such activity. The call discusses: 1. Vadadustat - still under FDA review, not approved, launch is ahead 2. Auryxia - existing product, continuing to grow revenue 3. European MAA submission - was submitted last month (October 2021), which is around the edge of the period 4. UT Health study expansion - investigator-sponsored study The European MAA submission is a regulatory filing, not a revenue-generating business activity. It's a submission, not a launch. The UT Health study expansion - this is a clinical trial expansion, not a commercial activity. Auryxia revenue growth - this is an established product performing well, not a new start. Vadadustat launch - this is still ahead, not yet happened. The PDUFA date is March 2022, about 5 months after the call. So there's no real business activity that "crossed from not-happening to happening" during the period. The main product (vadadustat) is still pending approval. The launch hasn't occurred. The European MAA submission is a regulatory milestone, not a business activity generating revenue. It's a filing, not a start of commercial activity. The UT Health study expansion is a clinical trial, not a commercial activity. Auryxia is an established product - its growth is the normal rhythm of an existing product.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| AIN | Albany International Corp. | Q3 2023 | 2023-11-07 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CARS | Cars.com Inc. | Q1 2023 | 2023-05-06 | B |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| SBSI | Southside Bancshares, Inc. | Q4 2017 | 2018-02-06 | A |
| ANIP | ANI Pharmaceuticals, Inc. | Q4 2016 | 2017-03-02 | B+ |
| PSX | Phillips 66 | Q4 2016 | 2017-02-03 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
AFL · Q2 2023 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the Japan Post cancer insurance launch in early April, which began selling the product and drove a 60% sales increase as a major contributor. They describe the activity as real and transacting, with Dan Amos noting the significant contribution from the new product. Yoshizumi confirms gradual increase going forward, and Fred highlights runway for more agents and sales calming down after initial jump, indicating the Q2 numbers reflect partial ramp-up rather than full run-rate.
ESE · Q2 2016 → YESThe question is about whether management's account of the just-reported period is built around real business activity that started partway through the period, and that the numbers average before and a...YES The transcript shows management's account centered on the real mid-period start of Plastique's contribution (acquired partway through Q2, with two months of performance noted and "early performance consistent with our acquisition forecast"), treated as a key new segment. It also explicitly addresses the incomplete climb, noting that the reported Q 2 numbers lag due to partial contribution and that Q3/Q4 will see fuller periods plus seasonality, with the business already running at a higher level as the ramp continues.
PSX · Q4 2016 → YESThe question is about whether management's account of the just-reported period is built substantially around real business activity that crossed from not-happening to happening partway through the per...YES The transcript shows management centering the Q4 story on the Freeport LPG Export Terminal's real start: commissioning completed smoothly, first commercial cargo shipped mid-December (partial Q4 contribution), with full-quarter costs incurred but only partial revenue, and explicit ramp to near-capacity loading in January onward.